Nilotinib for CML Leads to Fewer Treatment-Emergent Mutations Than Imatinib

CML patients treated with nilotinib had fewer treatment-emergent BCR-ABL mutations than those treated with imatinib, and among patients who did have a mutation, those treated with nilotinib had reduced rates of progression to accelerated phase and blast phase of the disease.
Source: Cancer Network - Category: Cancer & Oncology Source Type: news